Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys, Inc. reported developments tied to its home health, hospice and high-acuity care in the home operations and to its public-company status. Company updates covered operating and financial results, material agreements, capital-structure matters, and care delivery programs, including Contessa Health’s participation in a CMS dementia care payment model and recognition of home health and hospice care centers for patient and caregiver satisfaction.
In August 2025, Amedisys became a wholly owned subsidiary of UnitedHealth Group following a completed merger. The completed transaction changed Amedisys from a Nasdaq-listed operating company into a subsidiary, making corporate-status and capital-structure updates part of the company’s durable news record.
Amedisys, Inc. (NASDAQ: AMED) reported Q3 2022 financial results with a net service revenue increase to $558 million, but net income dropped to $25.6 million from $45 million in Q3 2021. Adjusted EBITDA also fell to $61.5 million. Year-to-date results showed a revenue rise to $1.66 billion, yet net income decreased to $86.9 million compared to $175 million in 2021. The company anticipates adjusted net service revenue between $2.224 billion and $2.230 billion for 2022. Amedisys is focused on partnerships to drive growth despite facing operational challenges.
Amedisys, Inc. (NASDAQ: AMED) will announce its third-quarter results on October 26, 2022, after market closure. The investor call is scheduled for 11:00 a.m. ET on October 27, 2022. Interested participants can join by calling either (877) 524-8416 or (412) 902-1028. A replay will be available until November 27, 2022. Amedisys specializes in home health, hospice, personal care, and high-acuity services, serving over 445,000 patients annually across 547 care centers in 36 states. For more details, visit the company's investor relations website.
Amedisys (NASDAQ: AMED) has partnered with the University of Arkansas for Medical Sciences (UAMS) and Contessa to introduce a comprehensive care-at-home program in Central Arkansas. This first-of-its-kind initiative includes Recovery Care, Rehabilitation Care, and Palliative Care at Home, allowing patients to receive essential medical services in their homes. The program aims to improve patient outcomes, increase access to care, and reduce overall healthcare costs. Services are set to begin later this year, boosting the region's healthcare offerings.
Amedisys, a leader in home health and hospice care, appointed Adam Holton as Chief People Officer on September 27, 2022. With over 20 years of HR experience, Holton aims to enhance talent acquisition and employee engagement strategies essential for the company's growth. Previously the Chief Human Resources Officer at Numotion and CHS, he brings extensive knowledge from various leadership roles, including his service as a Marine Corps Infantry Officer. Amedisys emphasizes that investing in human capital is vital for delivering high-quality patient care, especially in a competitive market.
Mount Sinai at Home, a joint venture between Mount Sinai Health System and Contessa, expands home-based care services in the New York area. This initiative combines home health, hospitalization, rehabilitation, and palliative care under the new name, aiming to enhance care delivery. The service currently treats nearly 3,000 patients annually, boasting a 96% patient satisfaction rate and a 4-star quality rating from CMS. Driven by patient demand for home care, this initiative aligns with emerging trends in healthcare delivery.
Amedisys, Inc. (AMED) reported a decrease in net service revenue, down $6.3 million to $557.9 million for Q2 2022. Net income was $29.6 million, a significant drop from $80.1 million in 2021, with EPS falling to $0.91 from $2.43. For the six-month period, revenue rose slightly to $1,103.1 million. Adjusted EBITDA also declined to $74.4 million. The company updated its 2022 revenue guidance to $2.290-$2.310 billion while reaffirming adjusted EBITDA guidance of $275-$285 million. CEO Chris Gerard noted challenges from COVID-19 and regulatory concerns.
Amedisys (NASDAQ: AMED) will disclose its Q2 results on July 27, 2022, post-market, with a conference call scheduled for July 28, 2022, at 11:00 a.m. ET. Investors can access the call by dialing toll-free numbers or via a live webcast on the company's investor relations site. Amedisys is dedicated to providing high-quality home health, hospice, personal care, and high-acuity care services across the U.S., partnering with over 3,000 hospitals and 90,000 physicians to deliver care to more than 445,000 patients annually.
Amedisys (NASDAQ: AMED) has partnered with Memorial Hermann Health System to provide home-based medical, rehabilitation, and palliative care. This collaboration allows patients to receive acute hospital care and rehabilitation in the comfort of their homes, reducing readmission rates by 44% and hospital stays by 35%. Patients will have the option to be discharged directly from the Emergency Center and monitored remotely. This innovative approach aligns with the growing trend towards community-based healthcare and enhances patient experience.
Summary not available.
Amedisys (NASDAQ: AMED) announced a partnership with Baylor Scott & White Health to offer innovative at-home care solutions. This collaboration aims to deliver hospital-level care, including skilled nursing and palliative support, reducing hospital readmission rates by 44% and hospital stays by 35%. The program, set to roll out in 2023, will enhance patient outcomes and satisfaction, building on Baylor Scott & White's century-long reputation for quality care. Both organizations are committed to improving patient experiences by providing more convenient care options in the comfort of home.